Naropa University and Center for Psychedelic Studies Separate
Naropa University’s Center for Psychedelic Studies has become an independent entity, the Memoru Center for Visionary Healing Arts, in...
Lerodalcibep Biologic License Application Submitted to FDA
LIB Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for Lerodalcibep, a novel PCSK9 inhibitor...
Contineum PIPE-791 Phase 1b PET Trial Begins Patient Dosing
Contineum Therapeutics has initiated a Phase 1b positron emission tomography (PET) trial for PIPE-791, a novel brain-penetrant, small molecule...
Navigating the Future of Endometriosis Diagnostics
In this interview, we spoke with Farideh Bischoff, PhD, Chief Medical Officer – Head of Diagnostics at HeranovaTM, about their innovative...
How Sangamo is Navigating the Future of Gene Therapy for Rare Diseases
In this interview, we speak with Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo Therapeutics, about the FDA’s accelerated approval...
Beigene’s Global MAT2A Inhibitor Licensing Deal
BeiGene, soon to be BeOne Medicines, has secured global licensing rights for SYH2039, a novel MAT2A inhibitor, from CSPC....
Zelenectide Pevedotin Program Updates & Nectin-4 Gene Amplification Strategy
Bicycle Therapeutics presented data at the 2024 San Antonio Breast Conference Symposium (SABCS) highlighting the enhanced anti-tumor activity of...
Positive Results for Lunresertib & Camonsertib Combo in Gynecologic Trial
Repare Therapeutics announced positive data from its Phase 1 MYTHIC trial combining lunresertib and camonsertib (Lunre+Camo) in patients with...
Corcept Catalyst Trial Shows Positive Results in Cushing’s Syndrome & Diabetes Treatment
Corcept Therapeutics’ Phase 4 CATALYST study demonstrated that Korlym® significantly improved blood sugar control in patients with both Cushing’s...
Tobevibart & Elebsiran Get Breakthrough & PRIME for Chronic Hep D
Tobevibart and elebsiran, developed by Vir Biotechnology for chronic hepatitis delta (CHD), have received Breakthrough Therapy designation from the...